{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:21:46Z","timestamp":1792408906784,"version":"4.4.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.lungcan.2022.08.008","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T11:26:21Z","timestamp":1660303581000},"page":"94-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial"],"prefix":"10.1016","volume":"172","author":[{"given":"Enriqueta","family":"Felip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert F.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Molina-Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urania","family":"Dafni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartomeu","family":"Massuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Berghmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"de Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passiglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Viteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Britschgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinead","family":"Cuffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Provencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Merkelbach-Bruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charitini","family":"Andriakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roswitha","family":"Kammler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ruepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Roschitzki-Voser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Stahel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.lungcan.2022.08.008_b0005","first-page":"100037","article-title":"Catalog of 5\u2032 fusion partners in RET+ NSCLC Circa 2020","volume":"1","author":"Ou","year":"2020","journal-title":"JTO Clin. Res. Rep."},{"issue":"35","key":"10.1016\/j.lungcan.2022.08.008_b0010","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.2012.44.1477","article-title":"RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer","volume":"30","author":"Wang","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2022.08.008_b0015","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/annonc\/mdw559","article-title":"Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial","volume":"28","author":"Lee","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2022.08.008_b0020","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.lungcan.2019.09.011","article-title":"A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma","volume":"138","author":"Hida","year":"2019","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2022.08.008_b0025","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2022.08.008_b0030","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/j.jtho.2016.08.126","article-title":"Clinical activity of alectinib in Advanced RET-rearranged non-small cell lung cancer","volume":"11","author":"Lin","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2022.08.008_b0035","doi-asserted-by":"crossref","first-page":"314","DOI":"10.21037\/tlcr-20-549","article-title":"Phase 1\/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)","volume":"10","author":"Takeuchi","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"issue":"9","key":"10.1016\/j.lungcan.2022.08.008_b0040","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of Selpercatinib in RET fusion-positive non\u2013small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.lungcan.2022.08.008_b0045","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222005955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222005955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:02:43Z","timestamp":1759237363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222005955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":9,"alternative-id":["S0169500222005955"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.08.008","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}